These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 18797166)

  • 1. Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism.
    Shigematsu T; Akizawa T; Uchida E; Tsukamoto Y; Iwasaki M; Koshikawa S;
    Am J Nephrol; 2009; 29(3):230-6. PubMed ID: 18797166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
    Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
    J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study.
    Ureña P; Jacobson SH; Zitt E; Vervloet M; Malberti F; Ashman N; Leavey S; Rix M; Os I; Saha H; Ryba M; Bencova V; Baños A; Zani V; Fouque D
    Nephrol Dial Transplant; 2009 Sep; 24(9):2852-9. PubMed ID: 19369690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of cinacalcet hydrochloride on bone histology in patients with secondary hyperparathyroidism.
    Yajima A; Akizawa T; Tsukamoto Y; Kurihara S; Ito A;
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S38-43. PubMed ID: 19032526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cinacalcet reduces vascular and soft tissue calcification in secondary hyperparathyroidism (SHPT) in hemodialysis patients.
    Aladrén Regidor MJ
    Clin Nephrol; 2009 Feb; 71(2):207-13. PubMed ID: 19203518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism.
    Susantitaphong P; Vadcharavivad S; Susomboon T; Singhan W; Dumrongpisutikul N; Jakchairoongruang K; Eiam-Ong S; Praditpornsilpa K
    Ren Fail; 2019 Nov; 41(1):326-333. PubMed ID: 31014177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone metabolism after cinacalcet administration in patients with secondary hyperparathyroidism.
    Yano S; Suzuki K; Sumi M; Tokumoto A; Shigeno K; Himeno Y; Sugimoto T
    J Bone Miner Metab; 2010; 28(1):49-54. PubMed ID: 19548062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism.
    Malluche HH; Monier-Faugere MC; Wang G; Frazã O JM; Charytan C; Coburn JW; Coyne DW; Kaplan MR; Baker N; McCary LC; Turner SA; Goodman WG
    Clin Nephrol; 2008 Apr; 69(4):269-78. PubMed ID: 18397701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes of cinacalcet and paricalcitol titration protocol for treatment of secondary hyperparathyroidism.
    Lazar E; Hebert K; Poma T; Stankus N
    Am J Nephrol; 2007; 27(3):274-8. PubMed ID: 17429197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism.
    Akiba T; Akizawa T; Tsukamoto Y; Uchida E; Iwasaki M; Koshikawa S;
    Ther Apher Dial; 2008 Apr; 12(2):117-25. PubMed ID: 18387159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
    Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S
    Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Retrospective assessment of effective and safety of cinacalcet for the treatment of secondary hyperparathyroidism depending on basal iPTH level].
    Mercadal Orfila G; Blasco Mascaró I
    Farm Hosp; 2012; 36(1):11-5. PubMed ID: 21514862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.
    Parfrey PS; Chertow GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Dehmel B; Trotman ML; Modafferi DM; Goodman WG
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4834-44. PubMed ID: 24108314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cinacalcet for managing secondary hyperparathyroidism in dialysis patients in clinical practice in Belgium: a 16-month observational study (ECHO-B).
    Debelle F; Meeus G; Dratwa M; Maes B; Vanholder R; Albert A; Schutyser E; Jadoul M
    Acta Clin Belg; 2013; 68(4):275-81. PubMed ID: 24455797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity.
    Frazão JM; Messa P; Mellotte GJ; Geiger H; Hagen EC; Quarles LD; Kerr PG; Baños A; Dehmel B; Urena P
    Clin Nephrol; 2011 Sep; 76(3):233-43. PubMed ID: 21888861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
    Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
    Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
    Wilkie M; Pontoriero G; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Zani VJ; Carter D; Messa P
    Nephron Clin Pract; 2009; 112(1):c41-50. PubMed ID: 19365139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
    Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA
    Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [German observational trial on secondary hyperparathyroidism therapy with cinacalcet (EARLY)].
    Reichel H; Braun J
    Dtsch Med Wochenschr; 2011 Jan; 136(4):123-8. PubMed ID: 21181622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.